May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Suppression of Acute and Recurrent IRBP-Induced Experimental Autoimmune Uveitis by Recombinant TCR Ligand in Lewis Rats
Author Affiliations & Notes
  • L. J. Karren
    Oregon Health and Science University, Portland, Oregon
    Casey Eye Institute/Ophthalmology,
  • G. G. Burrows
    Oregon Health and Science University, Portland, Oregon
    Neurology,
  • J. Mooney
    Oregon Health and Science University, Portland, Oregon
    Neurology,
  • G. Adamus
    Oregon Health and Science University, Portland, Oregon
    Casey Eye Institute/Ophthalmology,
  • Footnotes
    Commercial Relationships  L.J. Karren, None; G.G. Burrows, Artielle Immuno Therapeutics, Inc., F; J. Mooney, None; G. Adamus, None.
  • Footnotes
    Support  NIH Grant R41EY17781, Research to Prevent Blindness
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 4767. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. J. Karren, G. G. Burrows, J. Mooney, G. Adamus; Suppression of Acute and Recurrent IRBP-Induced Experimental Autoimmune Uveitis by Recombinant TCR Ligand in Lewis Rats. Invest. Ophthalmol. Vis. Sci. 2008;49(13):4767. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To examine the effectiveness of Recombinant T-cell Receptor ligands (RTLs) in the treatment of acute and recurrent EAU induced with IRBP peptide.

Methods: : We designed and tested RTL220 containing the α1 and β1 domains of MHC class II molecules linked to the uveitogenic IRBP 1177-1191 peptide in Lewis rats. EAU was induced by subcutaneous injection of 20 µg IRBP1177-1191 peptide in complete Freund’s adjuvant and M. Tuberculosis at 2 mg/ml. Recurrent EAU was induced by passive transfer of 5x106 IRBP1177-1191 peptide-specific and activated T cells. Uveitis was examined by clinical and histological scoring.

Results: : We designed different regiments of treatment with RTL220. The RTL220 treatment (0.3 mg/dose for 5 days) beginning on day 1 resulted in a delayed onset, a significant reduction in acute EAU severity, and showed protection of the retina from inflammatory damage. Treatment beginning at clinical onset was the most effective, showing complete protection from EAU at the clinical and histological levels. In addition, RTL220 protected the rats receiving passively transferred specific T cells from recurrent uveitis. Five-days of treatment applied at the time of the first bout followed by boosts once a week were effective in the prevention of subsequent attacks. Histological examination showed reduced migration of inflammatory cells into the eye or complete protection with significantly reduced pro-inflammatory cytokines.

Conclusions: : RTL220 can prevent and reverse clinical and histological EAU by preventing the recruitment of inflammatory cells into the eye. These findings suggest a possible clinical application of this novel class of peptide/MHC class II drugs for patients with posterior autoimmune uveitis.

Keywords: uveitis-clinical/animal model • autoimmune disease • inflammation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×